2018
DOI: 10.1016/j.jalz.2018.03.002
|View full text |Cite
|
Sign up to set email alerts
|

The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable

Abstract: The Alzheimer's Association's Research Roundtable met in November 2017 to explore the new National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease. The meeting allowed experts in the field from academia, industry, and government to provide perspectives on the new National Institute on Aging and the Alzheimer's Association Research Framework. This review will summarize the "A, T, N System" (Amyloid, Tau, and Neurodegeneration) using biomarkers and how this may be ap… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

3
105
0
1

Year Published

2018
2018
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 111 publications
(109 citation statements)
references
References 86 publications
(93 reference statements)
3
105
0
1
Order By: Relevance
“…Although it has been recommended that risk stratification be based on more accurate neuropathological changes, several current large‐scale AD prevention studies have targeted individuals based on AD genetic risk ( APOE4 status) . Individuals with one and two APOE4 allele(s) have a 3‐ and 15‐fold increased risk of AD, respectively .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Although it has been recommended that risk stratification be based on more accurate neuropathological changes, several current large‐scale AD prevention studies have targeted individuals based on AD genetic risk ( APOE4 status) . Individuals with one and two APOE4 allele(s) have a 3‐ and 15‐fold increased risk of AD, respectively .…”
Section: Discussionmentioning
confidence: 99%
“…Apolipoprotein E ε4 allele ( APOE4 ) carrier status is the strongest genetic risk factor for AD and has been used and recommended for risk stratification in AD therapeutic development trials . However, recently, it has been suggested that clinical trial inclusion should target AD pathological changes of AD . Cerebrospinal fluid (CSF)‐derived or positron emission tomography (PET) imaging biomarkers express physiological changes associated with disease pathology but are invasive or cost‐prohibitive .…”
Section: Introductionmentioning
confidence: 99%
“…Alzheimer's disease (AD) is an age‐related neurodegenerative disorder characterized by the development of Aβ‐plaques, neurofibrillary tangles and cognitive dysfunction . Motor dysfunction also develops in AD, and manifests as altered gait, hyperactivity and motor stereotypes .…”
Section: Introductionmentioning
confidence: 99%
“…Alzheimer Disease (AD) is an age‐related progressive neurodegenerative disorder and is the most frequent form of dementia in elderly persons . Mouse models are key to understanding the progression of AD and for developing new AD treatments .…”
Section: Introductionmentioning
confidence: 99%